We also demonstrated that NAPRT silencing sensitized NAPRT-proficient ovarian and pancreatic cancer cell lines to FK866 treatment, whereas the NAPRT-proficient wild-type counterparts were completely refractory to NAMPT inhibition [70]. This evidence concerns the gene NAPRT and familial pancreatic carcinoma.